Literature DB >> 3330562

Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect.

T Yoshimoto1, K Kado, F Matsubara, N Koriyama, H Kaneto, D Tsura.   

Abstract

Several peptides and peptide derivatives were tested for their inhibitory effect on prolyl endopeptidase and possible properties as anti-amnesic agents. Among the compounds tested, Z-Gly-Pro-CH2Cl, Z-Val-prolinal, Boc-Pro-prolinal, Z-Pro-prolinal, aniracetam and pramiracetam inhibited the enzyme activities at Ki values in the order of nM to microM, and the effect of the prolinal-containing peptide derivatives was specific for prolyl endopeptidase. Z-Pro-prolinal was the most effective inhibitor in vitro (Ki = 5 nM) and in vivo (50 to 70% inhibition in various organs of rat at a dose of 1 mumol/animal i.p.). Regional differences were observed in the effect of inhibitors on the brain enzyme activities: most active in mesencephalon, followed by striatum, cerebellum, hippocampus, hypothalamus; and inactive in cerebral cortex and medulla oblongata. In the passive avoidance learning test using rats, pretreatment with Z-Pro-prolinal prevented the induction of amnesia by scopolamine at the dose of 1 mumol/animal, i.p. Z-Val-prolinal, Z-Pyr-prolinal and Z-Gly-Pro-CH2Cl were also effective in the retention test at 24 and 48 h after the training trial. The antiamnesic effect of these compounds was approximately parallel to the in vitro inhibitory activities on prolyl endopeptidase. These results suggest the possibility that the inhibitors exhibit their anti-amnesic effect through the regulation of the enzyme activity in the brain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3330562     DOI: 10.1248/bpb1978.10.730

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  22 in total

1.  Catalysis of serine oligopeptidases is controlled by a gating filter mechanism.

Authors:  V Fülöp; Z Szeltner; L Polgár
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

2.  ZTTA, a prolyl endopeptidase inhibitor, potentiates the arginine-vasopressin-induced incorporation of [14C]leucine in rat amygdaloid and cortical slices.

Authors:  Y Shishido; T Tanaka; S Tanabe; M Furushiro; S Hashimoto; T Yokokura; S Shibata; S Watanabe
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

3.  Prolyl endopeptidase catalysis. A physical rather than a chemical step is rate-limiting.

Authors:  L Polgár
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

4.  Benzyloxycarbonylprolylprolinal, a transition-state analogue for prolyl oligopeptidase, forms a tetrahedral adduct with catalytic serine, not a reactive cysteine.

Authors:  A Kahyaoglu; K Haghjoo; F Kraicsovits; F Jordan; L Polgar
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

5.  Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family.

Authors:  Z Szeltner; V Renner; L Polgár
Journal:  Protein Sci       Date:  2000-02       Impact factor: 6.725

6.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

7.  Novel proline endopeptidase inhibitors do not modify Abeta40/42 formation and degradation by human cells expressing wild-type and swedish mutated beta-amyloid precursor protein.

Authors:  A Petit; H Barelli; P Morain; F Checler
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 8.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

9.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

10.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.